PRA Health Sciences Inc (NASDAQ:PRAH) (Trend Analysis) shares were traded with no significant volume change. The stock closed last trading session at $58.38, up by 0.09%, with a volume of 651,286 shares against an average amount for the last three months of 482,231.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
PRA Health Sciences Inc (NASDAQ:PRAH) stock is currently trading 4.23% below its 52-week-high, 63.99% above its 52-week-low. The 1-year stock price history is in the range of $35.6 – $60.96. PRA Health Sciences Inc (PRAH) has a price to earnings ratio of 45.33 versus Healthcare sector average of 40.79. PRAH stock price has outperformed the Nasdaq by 22.9%. The Medical Drugs company is currently valued at $3.58 billion, and its share price closed the last trading session at $58.38. The stock has a 50-day moving average of $55.32 and a 200-day moving average of $49.09.
PRA Health Sciences Inc (PRAH) current short interest stands at 1.28 million shares. It has increased by 7% from the same period of last month. Around 5% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.49 million shares, the number of days required to cover the short positions stand at 2.6 days.
PRA Health Sciences Inc (PRAH) declared last quarter earnings on November 02. The Medical Drugs company announced last quarter earnings per share of $0.62 against a consensus Street estimate of $0.62, matching the average estimate. The company posted a revenue of $453.3 million compared to an estimation of $398.6 million.
Is this a Trading Opportunity? Click here for a free Trend Analysis Report
There are currently eleven analysts that cover PRA Health Sciences Inc stock. Of those eleven, seven have a Buy rating, three have a Hold rating and one has a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $57.83.
A recent analyst activity consisted of UBS downgrading their Buy rating to Neutral on September 6. On the date of report, the stock closed at $49.62.
First Analysis initiated their coverage on the stock with Equal-weight rating on June 21. On the date of report, the stock closed at $42.48.
Another research firm was Credit Suisse who initiated their coverage on the stock with Neutral rating on June 21. Credit Suisse fixed their price target at $43. This translates to a 26.34% downside from the last closing price. On the date of report, the stock closed at $42.48.
PRA Health Sciences, Inc. is a global contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries.